

# SECURITIES AND EXCHANGE COMMISSION

## FORM 8-K

Current report filing

Filing Date: **2005-03-14** | Period of Report: **2005-03-14**

SEC Accession No. [0001090002-05-000073](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **XINO CORP**

CIK: **700890** | IRS No.: **930962072** | State of Incorporation: **DE** | Fiscal Year End: **1231**

Type: **8-K** | Act: **34** | File No.: **000-10965** | Film No.: **05678006**

SIC: **8090** Misc health & allied services, nec

#### Mailing Address

3355 NORTH ACADEMY BLVD  
SUITE 260  
COLORADO SPRINGS CO  
80916

#### Business Address

3355 NORTH ACADEMY BLVD  
SUITE 260  
COLORADO SPRINGS CO  
80916  
719-633-5301

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 14, 2005**

---

**XINO CORPORATION**

---

(Exact name of registrant specified in charter)

---

**Delaware**

(State of  
Incorporation)

**000-10965**

(Commission File  
Number)

**93-0962072**

(IRS Employer  
Identification No.)

**3355 North Academy Blvd., Suite 260, Colorado Springs, CO 80917**

(Address of principal executive offices) (Zip Code)

**(719) 633-5301**

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## ITEM 8.01 Other Events

The registrant, Xino Corporation (formerly Cita Biomedical, Inc.), disclosed in Item 2 of a Current Report on Form 8-K on August 20, 2003 (and reiterated the disclosure in a Current Report on Form 8-K dated May 12, 2004) that all of the collateral pledged by registrant to secure a \$300,000 loan, including all the rights in intellectual property and U.S. patents and virtually all other personal property of the registrant was sold at a foreclosure sale. As a result of the foreclosure, the Company has virtually no remaining operating assets and is no longer conducting the business operations formerly known as Cita Biomedical, Inc.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

XINO CORPORATION

Dated: March 14, 2005

By: /s/ Michael Hinton

-----  
Michael Hinton  
Chief Executive Officer